Sukeshi Arora MD
@drsukeshiarora
Yogi, medical oncologist caring for patients with GI cancers, she/her. Views are my own. Have a blessed day! @UTHealthSAMDA #GIcancers
insta: @yogaoncology
ID: 1156975789927256065
01-08-2019 17:11:38
3,3K Tweet
893 Followers
599 Following
Please see our award winning video on clinical trial diversity in partnership with Genentech and Enrique Diaz. Representation matters. salud-america.org/award-winning-β¦
- π«π. π΄ππππππ π«πππππππ: π¨ π³πππ πͺππ πΊππππ ππ πππππππ π½πππππππ. On the night of August 8th, a 31-year-old female doctor diligently completed her duty, as she had done countless times before. After finishing her shift, she shared a
A drug effective in treating breast cancer shows new promise in addressing breast cancer with brain metastases or recurrent glioblastoma, as reported by results of a prospective window-of-opportunity trial at the UT Health San Antonio. Read more here: ow.ly/cnf150T1zYW
Thanks to Melissa (Kah Poh) Loh, MBBCh BAO, MS, FACCC for leading this effort and to all co-authors! Sukeshi Arora MD Nina Rosa Neuendorff Fabio Gomes Jessica Krok-Schoen, PhD Teresa Amaral, MD, PhD Elene Mariamidze Etienne Brain Capu B NicolΓ² Battisti, MD Maxime frelaut Ravindran Kanesvaran Anna Mislang Christopher Steer Siri Rostoft
Marcela Mazo MD Unacceptable. Is this something ASCO Advocacy can support with Rep. Joaquin Castro and Rep. Rep. Tony Gonzales ? Sen Ted Cruz and Sen Senator John Cornyn can you work towards ensuring Texans have access to clinical trials? #LatinosInOncology
Meet David Haile, MD, one of our newest providers to join the team at UT Health San Antonio MD Anderson! He specializes in stem cell transplantation and treating benign blood disorders. (He also enjoys British mysteries and building book nooks.) Learn more: bit.ly/3X6lBL3
Thatβs a wrap. Together for Kamala Harris. Letβs go win this thing. #DemConvention
πDurable stable/partial response to atezo-beva in HCC Journal of Clinical Oncology βοΈβ Significant proportion of HCC tumors become ghost tumors (radiologically persistent without viable tumor cells) β‘οΈDurable: PR/SD >6 mo β‘οΈIMbrave150 βοΈCR, PR, SD: 8.9%, 22.1%, 44.2% βοΈ77.8% of PRs and 28.5%
Age-specific impact of comorbidity on postoperative outcomes in older patients with colorectal cancer geriatriconcology.net/article/S1879-β¦ William Dale, MD, PhD, FASCO Supriya Mohile Cancer and Aging Research Group (CARG) #GeriOnc #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Age #Comorbidity
Pre- and post-transplant patients and caregivers! Join us today for our upcoming Adult Transplant Support Group session as we provide a safe and supportive space to share, learn, and connect with others here University Health. Please see invite for more details!